Point72 Asset Management
IRWD icon

Point72 Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Point72 Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,532,565
Closed -$2.25M – 2402
2025
Q1 		$2.25M Buy
1,532,565
+381,557
+33% +$909K 0.01% 1215
2024
Q4 		$5.1M Buy
+1,151,008
New +$4.67M 0.01% 943
2024
Q1 		– Sell
-2,217,669
Closed -$25.4M – 2394
2023
Q4 		$25.4M Buy
2,217,669
+979,896
+79% +$9.69M 0.06% 373
2023
Q3 		$11.9M Buy
1,237,773
+105,894
+9% +$1.04M 0.03% 583
2023
Q2 		$12M Buy
1,131,879
+1,121,686
+11,004% +$12.1M 0.04% 534
2023
Q1 		$107K Buy
+10,193
New +$114K ﹤0.01% 1611
2021
Q1 		– Sell
-620,139
Closed -$7.06M – 1065
2020
Q4 		$7.06M Buy
+620,139
New +$6.79M 0.03% 522
2020
Q1 		– Sell
-79,913
Closed -$1.06M – 921
2019
Q4 		$1.06M Buy
+79,913
New +$881K 0.01% 700
2018
Q4 		– Sell
-45,611
Closed -$705K – 1085
2018
Q3 		$705K Sell
45,611
-1,250,006
-96% -$19.8M ﹤0.01% 897
2018
Q2 		$20.7M Buy
1,295,617
+1,218,007
+1,569% +$18M 0.08% 294
2018
Q1 		$1M Buy
+77,610
New +$967K ﹤0.01% 814
2017
Q3 		– Sell
-1,008,214
Closed -$15.9M – 962
2017
Q2 		$15.9M Sell
1,008,214
-935,639
-48% -$13.6M 0.09% 302
2017
Q1 		$27.8M Buy
1,943,853
+1,595,764
+458% +$21.8M 0.15% 180
2016
Q4 		$4.46M Sell
348,089
-790,900
-69% -$9.99M 0.03% 460
2016
Q3 		$15.1M Sell
1,138,989
-254,628
-18% -$2.98M 0.11% 226
2016
Q2 		$15.3M Sell
1,393,617
-15,900
-1% -$155K 0.1% 222
2016
Q1 		$12.9M Sell
1,409,517
-426,736
-23% -$3.52M 0.1% 238
2015
Q4 		$17.8M Sell
1,836,253
-88,953
-5% -$860K 0.15% 177
2015
Q3 		$16.8M Buy
1,925,206
+279,158
+17% +$2.6M 0.13% 218
2015
Q2 		$16.6M Buy
1,646,048
+750,548
+84% +$8.72M 0.12% 231
2015
Q1 		$12M Sell
895,500
-895,619
-50% -$11.8M 0.08% 294
2014
Q4 		$23M Buy
1,791,119
+247,874
+16% +$2.84M 0.16% 196
2014
Q3 		$16.7M Buy
+1,543,245
New +$17.7M 0.13% 209

Other funds holding IRWD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Point72 Asset Management's IRWD Position: Q2 2025 in Review

Point72 Asset Management sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2025, closing a stake of 1,532,565 shares — an estimated $2.25M sold.

Point72 Asset Management first reported a position in IRWD in Q3 2014 and held it in 23 quarters. The position peaked at $27.8M in Q1 2017. 155 funds tracked by Wall St. Rank hold IRWD as of Q2 2025.

  • Point72 Asset Management reported no remaining Ironwood Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Point72 Asset Management sold 1,532,565 Ironwood Pharmaceuticals shares in Q2 2025, an estimated $2.25M.
  • Point72 Asset Management first reported a position in Ironwood Pharmaceuticals in Q3 2014 and held it in 23 quarters.
  • Point72 Asset Management's Ironwood Pharmaceuticals position peaked at $27.8M in Q1 2017.
  • 155 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.